Levin AS, Bilous RW, Coresh J. Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19–62.
Iliescu EA, Yeates KE, Holland DC. Quality of sleep in patients with chronic kidney disease. Nephrol Dialysis Transpl. 2004;19(1):95–99.
Gopal A, Farragher J, Jassal SV, Mucsi I. Sleep disorders in CKD. Am J Kidney Dis. 2025.
Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997;20(11):1038–52.
Sohn JW. Network of hypothalamic neurons that control appetite. BMB Rep. 2015;48(4):229.
Gutstein H, Akil H. Opioid analgesics. In: Hardman J, Limbird L, Gilman A, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill;200.
Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24. https://doi.org/10.1016/j.smrv.2004.08.001.
Johns MW. A new method for measuring daytime sleepiness: the epworth sleepiness scale. Sleep. 1991;14(6):540–45.
Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliability and validity studies of the Turkish version of the epworth sleepiness scale. Sleep & Breathing = Schlaf & Atmung. 2008;12(2):161–68. https://doi.org/10.1007/s11325-007-0145-7.
Sanford SD, Lichstein KL, Durrence HH, Riedel BW, Taylor DJ, Bush AJ. The influence of age, gender, ethnicity, and insomnia on epworth sleepiness scores: a normative us population. Sleep Med: X. 2006;7(4):319–26.
Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Trends in Immunology. 1997;18(3):140-145.
Botte DAC. Avaliação do efeito anti-inflamatório do hormônio α estimulador de melanócito (Α MSH) em modelo experimental de lúpus. 2013. https://doi.org/10.11606/T.5.2013.tde-10122013-115118. Doctoral Thesis, Faculdade de Medicina, University of São Paulo, São Paulo.
Lee SY, Cho WY, Kim HK, Won NH. The effect of alpha-MSH on long-term histologic changes after acute ischemic kidney injury in rats. Korean J Nephrol. 2005;24(2):191–203.
Chiao H, Kohda Y, McLeroy P, Craig L, Linas S, Star RA. α-melanocyte-stimulating hormone inhibits renal injury in the absence of neutrophils. Kidney Int. 1998;54(3):765–74.
Oktar B, Alican İ. The actions of the Α-melanocyte stimulating hormone (Α-Msh) in inflammatory conditions. Marmara Med J. 2001;14(2):113–18.
Lee SY, Jo SK, Cho WY, Kim HK, Won NH. The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine a nephrotoxicity. Transplantation. 2004;78(12):1756–64.
Gong R. Leveraging melanocortin pathways to treat glomerular diseases. Adv Chronic Kidney Dis. 2014;21(2):134–51.
Chiu YL, Chuang YF, Fang KC, Liu SK, Chen HY, Yang JY, Tsai TJ. Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol Dialysis Transpl. 2009;24(1):247–51.
Korucu B, Erten YT, Yeter HH, Altinova A, Pasaoglu OT, Pasaoglu H, Sindel MS, Arinsoy ST, Yetkin I. Hypothalamic energy regulatory peptides in chronic kidney disease. Ther Apher Dial. 2019;23(5):437–43.
Amr EM, Montasser ZM, Amel FK. Inflammatory status in patients on chronic hemodialysis.2004.
Koch BC, van der Putten K, Van Someren EJ, Wielders JP, Ter Wee PM, Nagtegaal JE, Gaillard CA. Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (cream study). Nephrol, Dialysis, Transpl: Off Publ of The Eur Dialysis and Transpl Assoc – Eur Renal Assoc. 2010;25(2):513–19. https://doi.org/10.1093/ndt/gfp493.
Karasek M, Szuflet A, Chrzanowski W, Zylinska K, Swietoslawski J. Decreased melatonin nocturnal concentrations in hemodialyzed patients. Neuro Endocrinol Lett. 2005;26(6):653–56.
Elder SJ, Pisoni RL, Akizawa T, Fissell R, Andreucci VE, Fukuhara S, Saran R. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dialysis Transpl. 2008;23(3):998–1004.
Noda A, Nakai S, Soga T, Sugiura T, Iwayama N, Maeda K, Atarashi M, Yasuma F, Ozaki N, Yokota M, Koike Y. Factors contributing to sleep disturbance and hypnotic drug use in hemodialysis patients. Intern Med. 2006;45(22):1273–78.
Tan LH, Chen PS, Chiang HY, King E, Yeh HC, Hsiao YL, Chang DR, Chen SH, Wu MY, Kuo CC. Insomnia and poor sleep in CKD: a systematic review and meta-analysis. Kidney Med. 2022;4(5):100458.
Ahmad S, Gupta M, Gupta R, Dhyani M. Prevalence and correlates of insomnia and obstructive sleep apnea in chronic kidney disease. N Am J Med Sci. 2013;5(11):641–46.
Hui DS, Wong TY, Ko FW, Li TS, Choy DK, Wong KK, Szeto CC, Lui SF, Li PK. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis: The Off J Natl Kidney Foundation. 2000;36(4):783–88.
Nicholl DDM, Ahmed SB, Loewen AHS, Hemmelgarn BR, Sola DY, Beecroft JM, Turin TC, Hanly PJ. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest. 2012;141(6):1422–30.
Abdelwhab S, Kamel M, Noshey M. Sleep disorders in hemodialysis patients. Kidney. 2010;19:175–81.